Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets

Adenovirus Vector-Induced Innate Inflammatory Mediators, MAPK Signaling, As Well As Adaptive Immune Responses Are Dependent upon Both TLR2 and TLR9 In Vivo

(2014) D. M. Appledorn et al.   JOURNAL OF IMMUNOLOGY

Correction: PfRH5: A Novel Reticulocyte-Binding Family Homolog of Plasmodium falciparum that Binds to the Erythrocyte, and an Investigation of Its Receptor

(2014) Marilis Rodriguez et al.   PLoS One

Autophagy and the Immune System

(2012) Petric Kuballa et al.   Annual Review of Immunology

HIV vaccine design: the neutralizing antibody conundrum

(2012) Leonidas Stamatatos   CURRENT OPINION IN IMMUNOLOGY

Adjuvants for human vaccines

(2012) Carl R Alving et al.   CURRENT OPINION IN IMMUNOLOGY

Improved outlook on HIV-1 prevention and vaccine development

(2012) Sandhya Vasan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Recombinant Viral-Vectored Vaccines Expressing Plasmodium chabaudi AS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection

(2012) S. Biswas et al.   JOURNAL OF IMMUNOLOGY

Type I IFN Induced by Adenovirus Serotypes 28 and 35 Has Multiple Effects on T Cell Immunogenicity

(2012) M. J. Johnson et al.   JOURNAL OF IMMUNOLOGY

Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)

(2012) A. Duerr et al.   JOURNAL OF INFECTIOUS DISEASES

Antiviral Inhibitory Capacity of CD8+ T cells Predicts the Rate of CD4+ T-Cell Decline in HIV-1 Infection

(2012) Hongbing Yang et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

(2012) M. Bonsignori et al.   JOURNAL OF VIROLOGY

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

(2012) Susanne H Sheehy et al.   MOLECULAR THERAPY

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study

(2012) Barton F Haynes et al.   NATURE BIOTECHNOLOGY

Lessons learned from HIV-1 vaccine trials: new priorities and directions

(2012) Andrew J McMichael et al.   NATURE IMMUNOLOGY

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

High Affinity Antibodies to Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Malaria

(2012) Sreenivasulu B. Reddy et al.   PLoS One

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA

(2012) Toritse Orubu et al.   PLoS One

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

(2012) Matthew D. J. Dicks et al.   PLoS One

T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein

(2012) Emily K. Forbes et al.   PLoS One

A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults

(2012) Michael C. Keefer et al.   PLoS One

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

(2012) J. J. Moon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

(2012) S. Colloca et al.   Science Translational Medicine

Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

(2012) E. Barnes et al.   Science Translational Medicine

Malaria vaccines: Focus on adenovirus based vectors

(2012) Nathaniel J. Schuldt et al.   VACCINE

Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens

(2012) Andrew R. Williams et al.   PLoS Pathogens

Long-Term Humoral and Cellular Immune Responses Elicited by a Heterologous Plasmodium vivax Apical Membrane Antigen 1 Protein Prime/Adenovirus Boost Immunization Protocol

(2011) Leoneide Érica Maduro Bouillet et al.   INFECTION AND IMMUNITY

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

(2011) Jens Wrammert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ΔE1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum

(2011) Shan Zong et al.   JOURNAL OF GENE MEDICINE

The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus

(2011) S. C. de Cassan et al.   JOURNAL OF IMMUNOLOGY

CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria

(2011) A. Reyes-Sandoval et al.   JOURNAL OF IMMUNOLOGY

Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine

(2011) Lilin Lai et al.   JOURNAL OF INFECTIOUS DISEASES

Differential Effects of Viral Vectors on Migratory Afferent Lymph Dendritic Cells In Vitro Predict Enhanced Immunogenicity In Vivo

(2011) C. Cubillos-Zapata et al.   JOURNAL OF VIROLOGY

The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection

(2011) E. S. Gray et al.   JOURNAL OF VIROLOGY

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

Antibody-based protection against HIV infection by vectored immunoprophylaxis

(2011) Alejandro B. Balazs et al.   NATURE

Programming the magnitude and persistence of antibody responses with innate immunity

(2011) Sudhir Pai Kasturi et al.   NATURE

A Field Trial to Assess a Blood-Stage Malaria Vaccine

(2011) Mahamadou A. Thera et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccines against malaria

(2011) A. V. S. Hill   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1

(2011) Sumi Biswas et al.   PLoS One

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial

(2011) Beryl A. Koblin et al.   PLoS One

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

(2011) Gavin J. Churchyard et al.   PLoS One

A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity

(2011) Anna L. Goodman et al.   PLoS One

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

(2011) Martha Sedegah et al.   PLoS One

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

(2011) Cindy Tamminga et al.   PLoS One

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

(2011) X. Wu et al.   SCIENCE

Antibody Repertoire: Embracing Diversity

(2011) A. J. Pollard et al.   Science Translational Medicine

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

(2011) N. L. Letvin et al.   Science Translational Medicine

Targeting TLRs Expands the Antibody Repertoire in Response to a Malaria Vaccine

(2011) S. R. Wiley et al.   Science Translational Medicine

Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice

(2011) Christopher Palma et al.   VACCINE

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

(2011) Alexander D. Douglas et al.   Nature Communications

Blood-stage malaria vaccines — recent progress and future challenges

(2010) A. L. Goodman et al.   ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY

The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert

(2010) K. Radosevic et al.   Clinical and Vaccine Immunology

Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1

(2010) Robert M Paris et al.   Expert Review of Vaccines

Prime-boost vectored malaria vaccines: Progress and prospects

(2010) Adrian V. S. Hill et al.   Human vaccines & immunotherapeutics

Immunologic Basis of Vaccine Vectors

(2010) Margaret A. Liu   IMMUNITY

New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1

(2010) A. L. Goodman et al.   INFECTION AND IMMUNITY

Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines

(2010) S. J. Draper et al.   JOURNAL OF IMMUNOLOGY

Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors

(2010) E. G. Rhee et al.   JOURNAL OF VIROLOGY

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

(2010) Richard A. Koup et al.   PLoS One

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa

(2010) Walter Jaoko et al.   PLoS One

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant

(2010) X. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic immunization in the lung induces potent local and systemic immune responses

(2010) K. Song et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rabies vaccines: WHO position paper—Recommendations

(2010)   VACCINE

Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth

(2010) Joseph T. Bruder et al.   VACCINE

The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species

(2010) Lediya Cheru et al.   VACCINE

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

(2010) Mark A. Pierce et al.   VACCINE

Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1

(2010) Alexander D. Douglas et al.   VACCINE

Extreme CD8 T Cell Requirements for Anti-Malarial Liver-Stage Immunity following Immunization with Radiation Attenuated Sporozoites

(2010) Nathan W. Schmidt et al.   PLoS Pathogens

Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria

(2009) Simon J. Draper et al.   Cell Host & Microbe

Anti-Apical-Membrane-Antigen-1 Antibody Is More Effective than Anti-42-Kilodalton-Merozoite-Surface-Protein-1 Antibody in Inhibiting Plasmodium falciparum Growth, as Determined by the In Vitro Growth Inhibition Assay

(2009) K. Miura et al.   Clinical and Vaccine Immunology

Innate Immune Recognition of Viruses and Viral Vectors

(2009) Xiaopei Huang et al.   HUMAN GENE THERAPY

Mapping Epitopes of the Plasmodium vivax Duffy Binding Protein with Naturally Acquired Inhibitory Antibodies

(2009) P. Chootong et al.   INFECTION AND IMMUNITY

Cytokine-secreting follicular T cells shape the antibody repertoire

(2009) R Lee Reinhardt et al.   NATURE IMMUNOLOGY

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

(2009) Philip R Johnson et al.   NATURE MEDICINE

Viruses as vaccine vectors for infectious diseases and cancer

(2009) Simon J. Draper et al.   NATURE REVIEWS MICROBIOLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

(2009) Michele D. Spring et al.   PLoS One

High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model

(2009) Sheetij Dutta et al.   PLoS One

Immunization of Mice with a Recombinant Adenovirus Vaccine Inhibits the Early Growth of Mycobacterium tuberculosis After Infection

(2009) Edward O. Ronan et al.   PLoS One

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals

(2009) Ruth D. Ellis et al.   VACCINE

Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs

(2009) Constantinos S. Kyriakis et al.   VACCINE

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy

(2009) M. Dudareva et al.   VACCINE

Poxvirus-vectored vaccines for rabies—A review

(2009) Jacqueline Weyer et al.   VACCINE

Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome

(2009) Julie Delaloye et al.   PLoS Pathogens

Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses

(2008) R. Geiben-Lynn et al.   Clinical and Vaccine Immunology

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors againstPlasmodium berghei

(2008) Arturo Reyes-Sandoval et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Reticulocyte-binding protein homologue 5 – An essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum

(2008) Jake Baum et al.   INTERNATIONAL JOURNAL FOR PARASITOLOGY

Recombinant Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in Macaques

(2008) J. H. C. M. Kreijtz et al.   JOURNAL OF INFECTIOUS DISEASES

Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A

(2008) S. Sridhar et al.   JOURNAL OF VIROLOGY

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

(2008) Jinyan Liu et al.   NATURE

Effective induction of high-titer antibodies by viral vector vaccines

(2008) Simon J Draper et al.   NATURE MEDICINE

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

(2008) Yimin Wu et al.   PLoS One

Protection Induced by Plasmodium falciparum MSP142 Is Strain-Specific, Antigen and Adjuvant Dependent, and Correlates with Antibody Responses

(2008) Jeffrey A. Lyon et al.   PLoS One

Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements

(2008) Else Marie Agger et al.   PLoS One

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02

(2008) Meta Roestenberg et al.   PLoS One

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

(2007) Kazutoyo Miura et al.   VACCINE